Company GeNeuro SA

Equities

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:14 2024-03-28 pm EDT 5-day change 1st Jan Change
1.38 EUR +6.15% Intraday chart for GeNeuro SA +9.52% +26.61%

Business Summary

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Number of employees: 19

Managers

Managers TitleAgeSince
Chief Executive Officer 62 05-12-31
Founder 66 05-12-31
Director of Finance/CFO 62 15-10-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 21-05-26
Director/Board Member 81 08-07-15
Director/Board Member 75 15-03-16
Director/Board Member 72 15-07-20
Chief Executive Officer 62 05-12-31
Founder 66 05-12-31
Director/Board Member 43 20-05-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 24,999,028 18,367,974 ( 73.47 %) 109,605 ( 0.4384 %) 73.47 %

Shareholders

NameEquities%Valuation
Compagnie Merieux Alliance SAS
32.82 %
9,768,695 32.82 % 13 M €
Eclosion2 SA
21.40 %
6,367,608 21.40 % 9 M €
Servier SAS
4.589 %
1,365,659 4.589 % 2 M €
Financière Arbevel SA
0.6572 %
195,575 0.6572 % 269 843 €
OP Asset Management Ltd.
0.5629 %
167,524 0.5629 % 231 140 €
GENEURO SA
0.4728 %
140,716 0.4728 % 194 151 €
Auriga Capital Management LLC
0.2155 %
64,138 0.2155 % 88 494 €
IFS Independent Financial Services AG
0.1177 %
35,034 0.1177 % 48 338 €
NOVACAP Asset Management SA
0.0934 %
27,809 0.0934 % 38 369 €
Vega Investment Managers SA
0.0302 %
9,000 0.0302 % 12 418 €

Holdings

NameEquities%Valuation
140,716 0.47% 194,151 $

Company contact information

GeNeuro SA (Switzerland)

3, chemin du Pré-Fleur

1228, Plan-les-Ouates

+41 22 552 48 00

http://www.geneuro.ch
address GeNeuro SA(GNRO)

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.38 EUR
Average target price
4 EUR
Spread / Average Target
+189.86%
Consensus

Annual profits - Rate of surprise